NCT00526617View on ClinicalTrials.gov

A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

41

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

June 30, 2010

Conditions

Non-hematologic MalignanciesMetastatic MelanomaBreast CancerOvarian CancerPrimary Peritoneal CancerFallopian Tube CancerHepatocellular Carcinoma

Interventions

DRUG

ABT-888

Oral capsules

DRUG

Temozolomide

Oral capsules

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AbbVie

INDUSTRY